AB Science Announces Recruitment of First Patient in Phase 2B/3 Study of Masitinib in Rheumatoid Arthritis
PARIS--(BUSINESS WIRE)--Regulatory News: AB Science SA (Paris:AB) (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announced today the recruitment of the first patient in the phase 2b/3 study of masitinib in rheumatoid arthritis.